Search results
Results from the WOW.Com Content Network
Bromsulfthalein (also known as bromsulphthalein, bromosulfophthalein, and BSP) is a phthalein dye used in liver function tests. Determining the rate of removal of the dye from the blood stream gives a measure of liver function. [1] The mechanism by which the liver detoxifies BSP is to attach it to glutathione which is the body’s master ...
The liver is responsible for the production of the vast majority of coagulation factors. In patients with liver disease, international normalized ratio (INR) can be used as a marker of liver synthetic function as it includes factor VII, which has the shortest half life (2–6 hours) of all coagulation factors measured in INR. An elevated INR in ...
The LiMAx test is an innovative enzymatic liver function test. 13 C-methacetin, a selective metabolite of the liver specific cytochrome P450 1A2 is administered intravenously. Via the bloodstream the drug is transported to the liver and immediately metabolized to paracetamol and ultimately to 13 CO 2 (Fig. 1), which is in turn transported via ...
After hitting a September low, the US Dollar Index — which measures the dollar's value relative to a basket of six foreign currencies, including the euro, Japanese yen, British pound, Canadian ...
The U.S dollar's strength against other currencies is wreaking havoc in markets around the world ... 800-290-4726 more ways to reach us. Sign in. Mail. 24/7 Help. For premium support please call ...
The mighty US dollar flexed some muscle last week in a positive sign for Americans’ purchasing power. The US dollar index, which measures the currency’s strength against six of its peers ...
The comprehensive metabolic panel, or chemical screen (CMP; CPT code 80053), is a panel of 14 blood tests that serves as an initial broad medical screening tool. The CMP provides a rough check of kidney function, liver function, diabetic and parathyroid status, and electrolyte and fluid balance, but this type of screening has its limitations.
Conatus' (CNAT) emricasan fails to meet the primary endpoint in the phase IIb ENCORE-LF study on decompensated NASH cirrhosis patients while the ENCORE-PH probe falls shy of the predefined objectives.